ZEAL 📈 Zealand Pharma - Overview

Zealand Pharma A/S is a biotechnology company that specializes in the discovery, development, and commercialization of peptide-based medicines, with a strong focus on addressing unmet medical needs in Denmark and beyond. The company's portfolio is comprised of a range of medicines that target gastrointestinal and metabolic diseases, as well as other specialty disease areas where existing treatments are inadequate. By leveraging its expertise in peptide-based therapies, Zealand Pharma A/S aims to improve treatment outcomes for patients with complex and debilitating conditions.

The company's product lineup includes Dasiglucagon, a single-use syringe or autoinjector designed to treat severe hypoglycemia, a condition that can be life-threatening if left untreated. Additionally, Zealand Pharma A/S is developing Dasiglucagon bi-hormone artificial pancreas systems, which combine insulin and dasiglucagon to provide a more comprehensive treatment approach. These systems have the potential to revolutionize the management of diabetes and other metabolic disorders. The company's pipeline is further bolstered by the development of glepaglutide, a long-acting GLP-2 analog that is currently in Phase III clinical trials for the treatment of short bowel syndrome, a rare and debilitating condition that requires careful management.

With a strong foundation in research and development, Zealand Pharma A/S has established itself as a leader in the biotechnology industry. The company's commitment to innovation and patient-centricity has driven its growth since its incorporation in 1997. Headquartered in Søborg, Denmark, Zealand Pharma A/S continues to push the boundaries of medical science, with a focus on developing targeted therapies that address the complex needs of patients with gastrointestinal and metabolic diseases. For more information, investors and stakeholders can visit the company's website at https://www.zealandpharma.com, or review its financial disclosures, including its ISIN: DK0060257814, which is classified as a common stock under the GICS Sub Industry: Biotechnology.